Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Acta Neuropathol. 2021 Mar 7;141(5):651–666. doi: 10.1007/s00401-021-02279-2

Table 1:

Demographics and case characteristics for analysis of tauopathies.

Diagnosis n Age (mean, sd) Female (n, %) PMI (mean, sd) CDR (median, IQR) ABC Score
HCa 5 78, 10 5, 100% 8.2, 2.4 0, 0 A0B1C0 (1)
A1B1C0 (2)
A1B1C1 (1)
A2B0C0 (1)
AD 5 66, 5 2, 40% 8.6, 0.9 3, 0 A3B3C3 (5)
AGD 5 84, 12 1, 20% 8.7, 4.1 0.5, 0 A?B1C1 (1)
A?B2C1 (1)
A0B2C0 (1)
A1B2C0 (2)
CBD 5 66, 4 2, 40% 9.3, 2.7 1, 2.5 A1B1C0 (5)
PiD 5 68, 8 2, 40% 10.2, 3.9 3, 0 A0B0C0 (1)
A1B0C0 (1)
A1B1C0 (2)
A1B0C1 (1)
PSP 5 76, 10 3, 60% 11.1, 4.9 0.5, 0 A0B0C0 (1)
A0B1C0 (3)
A1B1C0 (1)
Total 30 73, 10 15, 50% 9.3, 3.3 0.75, 2.5 A0B0C0 (2)
A0B1C0 (4)
A0B2C0 (1)
A1B0C0 (1)
A1B0C1 (1)
A1B1C0 (10)
A1B1C1 (1)
A1B2C0 (2)
A2B0C0 (1)
A3B3C3 (5)
A?B1C1 (1)
A?B2C1 (1)
a

One of the HC cases had inclusions of α-synuclein in the form of Lewy bodies in the brain stem; however, none noted in the cortex.

Abbreviations: HC, Healthy Controls; AD, Alzheimer’s disease; AGD, Argyrophilic Grain Disease; CBD, Corticobasal Degeneration; PiD, Pick’s disease; PSP, Progressive Supranuclear Palsy; PMI, Postmortem Interval; CDR, Clinical Dementia Rating